Insulin Delivery Devices Market Poised for Steady Growth by 2032, Fueled by Innovation and Rising Diabetes Cases | DelveInsight

The global insulin delivery devices market size is expected to increase from USD 35,587.79 million in 2024 to USD 52,983.06 million by 2032, reflecting strong and sustained growth.
The global insulin delivery devices market was valued at USD 15.51 billion in 2023 and is expected to reach USD 26.35 billion by 2030, registering a CAGR of 9.28% from 2024 to 2030. This growth is primarily driven by the increasing prevalence of diabetes, influenced by lifestyle changes, aging populations, and genetic factors. Greater public awareness and education on diabetes management have also contributed, enabling patients and healthcare providers to recognize the benefits of advanced insulin delivery systems, including improved precision, user-friendliness, and better blood glucose control.

Technological innovations have further accelerated market growth, with developments such as smart insulin pumps, integration with continuous glucose monitoring (CGM) devices, and mobile app connectivity enhancing overall diabetes care. These advancements are fostering wider adoption of modern insulin delivery devices, supporting improved patient outcomes throughout the forecast period.

DelveInsight's Insulin Delivery Devices Market Insights report offers comprehensive analysis, including current and forecast market trends, leading company market shares, challenges, drivers, barriers, and key players in the insulin delivery devices sector.

Request for a sample report @ https://www.delveinsight.com/report-store/insulin-delivery-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

During the ERS Congress 2025 in September 2025, several biotechnology and pharmaceutical companies shared notable advancements in pulmonary and cardiopulmonary research:

*
In September 2025, Diagonal Therapeutics presented new preclinical data highlighting the potential of its lead clustering antibody, DIAG723, as a disease-modifying therapy for pulmonary arterial hypertension (PAH).

*
In September 2025, a study revealed that babies raised with dogs may have a reduced risk of developing childhood asthma.

*
In September 2025, Savara shared data from the Phase 3 IMPALA-2 trial of Molgramostim Inhalation Solution for patients with autoimmune pulmonary alveolar proteinosis (aPAP).

*
In September 2025, AllRock Bio, Inc. reported encouraging Phase 1 results for ROC-101, a first-in-class oral pan-ROCK inhibitor for cardiopulmonary and fibrotic diseases.

*
In September 2025, Gossamer Bio, Inc., in collaboration with Chiesi Group, announced five scientific presentations on seralutinib for PAH and PH-ILD.

*
In September 2025, Boehringer Ingelheim presented pooled analyses from the Phase III FIBRONEER Trademark program on nerandomilast, an investigational oral PDE4B inhibitor, showing a nominally significant reduction in mortality risk across IPF and PPF.

*
In September 2025, Kaia Health launched a pilot program of Kaia Breathe, a digital pulmonary rehabilitation solution for COPD patients, in partnership with MedImprove.

*
In September 2025, aTyr Pharma, Inc. shared additional findings from the Phase 3 EFZO-FIT Trademark study of efzofitimod in 268 patients with pulmonary sarcoidosis, a key form of interstitial lung disease.

Key Takeaways from the Insulin Delivery Devices Market Report

*
The Insulin Delivery Devices market is expected to register moderate growth at a steady CAGR between 2025 and 2032.

*
According to DelveInsight estimates, North America is likely to lead the global insulin delivery devices market during the forecast period.

*
The market is anticipated to expand further as awareness of diabetes rises and more advanced, effective interventions are developed.

*
Prominent companies operating in the insulin delivery devices sector include Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV, Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd, Ocean (Hangzhou) Medical Technology Co Ltd, Owen Mumford, SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD, and others

To read more about the latest highlights related to the Insulin Delivery Devices market, get a snapshot of the key highlights entailed in the Global Insulin Delivery Devices Market Report [https://www.delveinsight.com/sample-request/insulin-delivery-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Insulin Delivery Devices Overview

Insulin delivery devices are vital tools that enable effective management of blood glucose levels in individuals with diabetes. By offering alternatives to conventional syringes, these devices enhance convenience, accuracy, and patient adherence to insulin therapy.

Contemporary insulin delivery solutions include insulin pens, syringes, insulin pumps, and patch pumps, increasingly integrated with smart technologies such as mobile apps and continuous glucose monitoring (CGM) systems. These advancements make insulin administration more personalized, discreet, and efficient.

The rising global prevalence of diabetes-affecting both aging populations and younger individuals-is driving demand for advanced insulin delivery systems. Increased awareness, supportive healthcare policies, and ongoing research and development are further propelling market growth and improving diabetes management outcomes worldwide.

Insulin Delivery Devices Market Insights

North America is expected to lead the insulin delivery devices market in 2023, driven largely by the region's increasing prevalence of diabetes. This growth is reinforced by the strong presence of key industry players engaged in activities such as mergers, acquisitions, and strategic reimbursement initiatives. Additionally, heightened public awareness, along with a continuous flow of product approvals and new launches, is contributing to the region's expanding market share.

According to the Centers for Disease Control and Prevention (CDC), approximately 38.4 million people of all ages in the U.S.-about 11.6% of the population-lived with diabetes in 2021. Among adults aged 18 and older, 38.1 million individuals, representing 14.7% of the adult population, were affected. These statistics highlight the substantial demand for advanced insulin delivery solutions throughout North America.

To know more about why North America is leading the market growth in the Insulin Delivery Devices market, get a snapshot of the Insulin Delivery Devices Market Outlook [https://www.delveinsight.com/report-store/insulin-delivery-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Insulin Delivery Devices Market Dynamics

According to the International Diabetes Federation (IDF), approximately 537 million adults aged 20-79 were living with diabetes in 2021, a figure projected to increase to 643 million by 2030 and 783 million by 2045. The report also highlighted that around 21.1 million live births globally (16.7%) were affected by hyperglycemia during pregnancy, with women over 45 or those with a history of gestational diabetes facing a higher risk of developing type 2 diabetes later in life.

Additionally, the IDF Diabetes Atlas 2022 reported that out of 8.75 million people worldwide living with Type 1 diabetes, 1.52 million were under 20 years old. Interestingly, 62% of new Type 1 diabetes diagnoses occurred in individuals aged 20 or older, emphasizing the importance of insulin delivery devices that cater to both pediatric and adult patients. Younger patients, in particular, benefit from convenient and discreet solutions such as smart pens and patch pumps, driving demand for innovative, lifestyle-compatible devices.

The market is also experiencing a notable shift toward wearable insulin delivery technologies. Insulin pumps and patch pumps offer continuous, discreet insulin administration, aligning with patient preferences for convenience and mobility. A key development in this space includes PharmaSens, a Swiss medical device company, which submitted its FDA application in January 2024 for the "niia essential" insulin patch pump system in the U.S. This follows the company's ISO 13485 certification in November 2023 for its insulin pump design, development, manufacturing, and distribution processes, underscoring a strong focus on patient-centered innovation.

Insulin Delivery Devices Market Drivers:

The increasing demand for insulin delivery devices is largely driven by the rising prevalence of diabetes, influenced by lifestyle changes, an aging population, and genetic factors. Furthermore, awareness campaigns and educational initiatives have improved public understanding of diabetes management. Consequently, both patients and healthcare providers are increasingly appreciating the benefits of modern insulin delivery systems, which offer improved dosing accuracy, enhanced convenience, and more effective blood glucose control compared to traditional methods.

Get a sneak peek at the Insulin Delivery Devices market dynamics @ https://www.delveinsight.com/sample-request/insulin-delivery-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Coverage: Global

Study Period: 2022 to 2032

Key Insulin Delivery Devices Companies: Becton, Dickinson and Company, Medtronic, Novo Nordisk A/S, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Biocon Ltd., Eli Lilly and Company, Insulet Corporation, Abbott, Terumo, CeQur, EOFLOW CO., LTD, European Pharma Group BV , Roche, Sanofi, Hindustan Syringes & Medical Devices Ltd , Ocean (Hangzhou) Medical Technology Co Ltd, Owen Mumford, SOOIL Developments Co., Ltd, SUNGSHIM MEDICAL CO., LTD., and others.

Which MedTech key players in the Insulin Delivery Devices market are set to emerge as the trendsetter, explore @ Insulin Delivery Devices Companies [https://www.delveinsight.com/report-store/insulin-delivery-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Insulin Delivery Devices Market Report Introduction

2. Insulin Delivery Devices Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Insulin Delivery Devices Market Key Factors Analysis

6. Insulin Delivery Devices Market Porter's Five Forces Analysis

7. Insulin Delivery Devices Market Layout

8. Insulin Delivery Devices Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=insulin-delivery-devices-market-poised-for-steady-growth-by-2032-fueled-by-innovation-and-rising-diabetes-cases-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.